γ-Secretase

Cat. No.

A37243

CAS No.

851600-86-7

ELN318463

ELN318463 is a selective inhibitor of γ-secretase, targeting the amyloid precursor protein (APP). It demonstrates differential inhibition of presenilin 1 (PS1) and presenilin 2 (PS2) γ-secretase complexes, with EC50 values of 12 nM and 656 nM, respectively, showcasing a 51-fold greater selectivity for PS1. This compound is primarily utilized in research focused on Alzheimer's disease and related neurodegenerative disorders, making it a valuable tool for studies investigating APP processing and amyloid plaque formation.

Cat. No.

A37244

CAS No.

1146594-85-5

(R)-JNJ-40418677

(R)-JNJ-40418677 is the R-enantiomer of the compound JNJ-40418677, which functions primarily as a selective modulator of the mGlu2 receptor. This compound exhibits promising biological activity by potentially enhancing cognitive functions and mitigating anxiety-related behaviors. Research applications include studies on neuropharmacology and the investigation of therapeutic targets for neurological disorders.

Cat. No.

A37245

CAS No.

2085780-85-2

(-)-FRM-024 (l-FRM-024)

(-)-FRM-024 is a potent γ-secretase modulator that effectively penetrates the central nervous system. This compound is instrumental in Alzheimer’s disease research, facilitating the study of amyloid precursor protein processing and its implications in neurodegeneration. Its ability to modulate γ-secretase activity makes it a valuable tool for exploring therapeutic interventions in Alzheimer's pathology.

Cat. No.

A37246

CAS No.

1420200-82-3

γ-Secretase modulator 4

γ-Secretase modulator 4 is a potent modulator of the γ-secretase enzyme, characterized by its ability to effectively reduce Aβ42 peptide levels with IC50 values of 0.014 μM in human samples and 0.017 μM in mouse samples. This compound has significant implications in Alzheimer's research, particularly in the study of amyloid-beta production and the related pathophysiology. Its mechanism of action makes it a valuable tool for investigations into therapeutic strategies targeting Alzheimer's disease.

Cat. No.

A37247

CAS No.

504428-17-5

(1R,3S)-Compound E

(1R,3S)-Compound E is the isomer of Compound E and serves as an experimental control in research studies. As a γ-secretase inhibitor, it effectively blocks the cleavage of β-amyloid(40), β-amyloid(42), and Notch with IC50 values of 0.24, 0.37, and 0.32 nM, respectively. This compound is valuable for investigating Alzheimer's disease mechanisms and γ-secretase-related signaling pathways.

Cat. No.

A37249

CAS No.

2226077-86-5

(9R)-RO7185876

(9R)-RO7185876 is a selective inhibitor of γ-secretase, targeting the cleavage of amyloid precursor protein. This compound significantly reduces the secretion of Aβ42 peptides, making it a valuable tool for research on Alzheimer's disease and related disorders, such as cerebral amyloid angiopathy and multi-infarct dementia. Additionally, (9R)-RO7185876 may be utilized to investigate conditions associated with amyloid deposition, including dementia pugilistica and Down syndrome.

Cat. No.

A37250

CAS No.

2741571-83-3

gamma-secretase modulator 1 hydrochloride

Gamma-Secretase Modulator 1 Hydrochloride acts as a modulator of gamma-secretase, a crucial enzyme implicated in the pathogenesis of Alzheimer's disease. This compound is designed to influence the processing of amyloid precursor protein (APP), ultimately affecting the production of amyloid-beta peptide. Its potential applications include studying the modulation of amyloid-beta levels and investigating therapeutic strategies for Alzheimer's disease and related neurodegenerative disorders.

Cat. No.

A37251

CAS No.

2443487-67-8

Nivegacetor

Synonyms: RG6289

Nivegacetor is a potent γ-secretase modulator that plays a critical role in the modulation of amyloid precursor protein processing. By influencing the activity of γ-secretase, Nivegacetor is valuable for research into Alzheimer's disease and other neurodegenerative conditions. Its ability to alter the production of amyloid-beta peptides makes it a useful tool for exploring therapeutic pathways and understanding the molecular mechanisms underlying these diseases.

Cat. No.

A37252

CAS No.

2582757-69-3

Aβ42-IN-1

Aβ42-IN-1 is a potent γ-secretase modulator (GSM) designed to target the enzymatic cleavage of amyloid precursor protein, effectively lowering amyloid-beta 42 (Aβ42) levels. With an IC50 value of 0.091 μM, Aβ42-IN-1 demonstrates significant inhibition of Aβ42 production while avoiding CYP3A4 inhibition, indicating a favorable safety profile. Its sustained pharmacokinetic properties make it a valuable tool for research into Alzheimer's disease and related neuropathologies. This compound holds promise for exploring therapeutic strategies aimed at modulating γ-secretase activity in neurodegenerative disorders.

Cat. No.

A37253

CAS No.

2434633-17-5

Aβ42-IN-1 free base

Aβ42-IN-1 free base is a potent γ-secretase modulator that exhibits high oral bioavailability and significant brain penetration. This compound effectively lowers Aβ42 levels with an IC50 of 0.091 μM, demonstrating substantial reduction of brain Aβ42 levels in murine models. Aβ42-IN-1 free base holds considerable potential for therapeutic applications in Alzheimer's disease research.

Cat. No.

A37255

CAS No.

656810-87-6

MK-0752 sodium

MK-0752 sodium is a potent, orally bioavailable inhibitor of γ-secretase, exhibiting a dose-dependent reduction of Aβ40 with an IC50 of 5 nM in human SH-SY5Y cells. This compound effectively crosses the blood-brain barrier and demonstrates the ability to decrease newly generated central nervous system Aβ levels in vivo. MK-0752 sodium is primarily utilized in research on Alzheimer’s disease and other neurodegenerative disorders linked to amyloid-beta pathology.

Cat. No.

A37256

CAS No.

2694817-84-8

γ-Secretase modulator 10

γ-Secretase modulator 10 is a selective modulator of the γ-secretase enzyme complex. It influences the cleavage of amyloid precursor protein (APP), thereby altering the production of amyloid β peptides associated with Alzheimer's disease pathogenesis. This compound is valuable for research applications focused on neurodegenerative diseases and therapeutic strategies aimed at modulating γ-secretase activity.

Cat. No.

A37257

CAS No.

1420200-85-6

γ-Secretase modulator 14

γ-Secretase modulator 14 is a selective modulator of the γ-secretase complex, influencing the cleavage of amyloid precursor protein (APP). This compound exhibits potential in Alzheimer's disease research by altering the production of amyloid-beta peptides. Its utility extends to investigating the mechanisms underlying neurodegenerative disorders and developing novel therapeutic strategies aimed at modulating γ-secretase activity.

Cat. No.

A37258

CAS No.

2434630-29-0

γ-Secretase modulator 11

γ-Secretase modulator 11 functions as a potent γ-secretase inhibitor, effectively reducing levels of amyloid beta 42 in vitro and demonstrating significant brain penetration. This compound exhibits minimal inhibition of cytochrome P450 enzymes, highlighting its selective profile. Additionally, γ-secretase modulator 11 has shown considerable efficacy in alleviating cognitive deficits in Alzheimer's disease model mice, making it a valuable tool for research in neurodegenerative disorders.

Cat. No.

A37259

CAS No.

2436239-00-6

BPN-15606 besylate

BPN-15606 besylate is a potent orally active γ-secretase modulator (GSM) that effectively reduces the production of Aβ42 and Aβ40 peptides in SHSY5Y neuroblastoma cells, exhibiting IC50 values of 7 nM and 17 nM, respectively. This compound has demonstrated the ability to lower Aβ42 and Aβ40 levels in the central nervous system of rodent models. Additionally, BPN-15606 besylate features favorable pharmacokinetic and pharmacodynamic properties, including good bioavailability, optimal half-life, and manageable clearance rates, making it valuable for Alzheimer's disease research and neurodegenerative studies.

Cat. No.

A37260

CAS No.

1263871-36-8

BMS-932481

BMS-932481 is a potent γ-secretase modulator that demonstrates selective reduction of β-amyloid peptides Aβ1-42 and Aβ1-40, exhibiting IC50 values of 6.6 nM and 25.3 nM, respectively. This compound is valuable for research into Alzheimer's disease and mechanisms of amyloid plaque formation, offering insights into potential therapeutic strategies targeting γ-secretase activity.

Cat. No.

A37262

CAS No.

362653-62-1

GSI-18

GSI-18 is a potent γ-secretase inhibitor that disrupts Notch signaling, contributing to its anticancer properties. This compound effectively inhibits the attachment-free growth of pancreatic cancer cells, making it valuable for research into cancer biology and therapeutic interventions. Its mechanism of action offers insights into the regulation of cell proliferation and differentiation in oncogenic contexts.

Cat. No.

A37263

CAS No.

1444006-79-4

ELND 007

ELND 007 is a selective γ-secretase inhibitor that primarily targets the reduction of amyloid beta (Aβ) generation while minimizing inhibition of Notch signaling. It demonstrates significant biological activity in both in vitro and in vivo settings, effectively decreasing Aβ levels. This compound has shown potential therapeutic benefits for Alzheimer’s disease, particularly as evidenced by reductions in Aβ levels observed in cerebrospinal fluid during human clinical trials, following a strategic emphasis on metabolic stability and chirality in its development.

Cat. No.

A37264

CAS No.

564462-36-8

γ-secretase-IN-2

γ-Secretase-IN-2 is a potent inhibitor of γ-secretase, demonstrating an IC50 of 0.06 nM. This compound is instrumental in researching Alzheimer's disease, providing insights into the enzymatic processes involved in neurodegeneration. Its high efficacy makes it a valuable tool for studying the pathophysiology of Alzheimer's and exploring potential therapeutic strategies.

Cat. No.

A37265

CAS No.

2064292-78-8

LY3056480

LY3056480 is a potent γ-secretase inhibitor that targets Notch signaling pathways. This compound has demonstrated efficacy in enhancing recovery from mild to moderate sensorineural hearing loss, while exhibiting a favorable safety profile. Additionally, intratympanic administration of LY3056480 has been shown to promote hair cell regeneration and contribute to partial auditory recovery in mammalian models, making it a valuable tool for research in hearing restoration and neurodegenerative studies.

Cat. No.

A37267

CAS No.

2204249-82-9

γ-Secretase modulator 12

γ-Secretase modulator 12 is a selective modulator of γ-secretase, specifically designed to reduce levels of amyloid-β42 (Aβ42) with an IC50 of 0.39 µM. This compound is valuable for investigating Alzheimer's disease mechanisms and potential therapeutic interventions. Additionally, γ-secretase modulator 12 demonstrates favorable pharmacokinetics with a good brain-to-plasma ratio (Kp, brain = 0.72) in murine models, making it suitable for in vivo studies.

Cat. No.

A37268

CAS No.

2434630-30-3

γ-Secretase modulator 11 hydrochloride

γ-Secretase modulator 11 hydrochloride is a potent modulator of γ-secretase with an IC50 of 0.029 µM, demonstrating oral bioavailability. It effectively reduces brain Aβ42 levels, a critical factor in Alzheimer's disease pathology. Furthermore, this compound has shown the capability to improve cognitive deficits in Alzheimer's disease model mice, making it valuable for research into therapeutic strategies targeting Alzheimer's disease.

Cat. No.

A37269

CAS No.

398515-96-3

III-31-C

III-31-C is a hydroxyethyl urea-based inhibitor of γ-secretase. It demonstrates potent inhibition of amyloid-beta (Aβ) production, with an IC50 value of 10 nM in a cell-free γ-secretase assay and 200 nM in APP-transfected cells. This compound is relevant for research focused on Alzheimer's disease and offers valuable insights into the modulation of Aβ metabolism.

Cat. No.

A37270

CAS No.

1235493-78-3

BMS-869780

BMS-869780 is an orally active γ-secretase modulator that selectively regulates γ-secretase activity to modify the production profile of β-amyloid proteins. It alters the relative levels of specific β-amyloid subtypes while not inhibiting the overall production of β-amyloid proteins. Additionally, BMS-869780 demonstrates a synergistic effect when used in combination with acidic γ-secretase modulators, resulting in a reduction of total β-amyloid production in cell cultures. This compound is valuable for research into Alzheimer’s disease and related neurodegenerative disorders.

Cat. No.

A37271

CAS No.

1402002-76-9

PF-06442609

PF-06442609 is an orally active γ secretase modulator that effectively inhibits amyloid-beta (Aβ42) production with an IC50 of 6 nM. This compound demonstrates excellent brain penetration, making it suitable for research in neurodegenerative disease models, particularly Alzheimer's disease. Its modulatory effects on γ secretase activity provide valuable insights into the mechanistic understanding of amyloid plaque formation and associated pathologies.